The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Abyrx sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Abyrx develops, manufactures, and commercializes therapeutic devices and biosurgical products for use during surgical procedures. It also offers absorbable hemostatic bone putty used for light to moderate bleeding bone; Hemasorb, Hemasorb apply, Hemasorb plus; and montage which is used for moderate to heavy bleeding bone. It is also developing osteoinductive settable bone putty, soft tissue hemostat/adhesive and fixation hardware, and local drug delivery system. The company supplies products through its distributor KAIRUKU platform. It is headquartered in Stamford, Connecticut, the US. Key subsidiaries of Abyrx include Doctors Research Group.
The key metrics of Abyrx related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Abyrx is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Abyrx.
For a detailed understanding of the performance of Abyrx, buy the report here.